相关实验视频

Updated: Jun 29, 2025

Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice

Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice

Published on: March 10, 2015

胃肠病学家的小分子药物相互作用指南,用于炎症性肠道疾病

Sivan Harnik¹, Bella Ungar¹, Ronen Loebstein²

¹Department of Gastroenterology, Sheba Medical Center Tel Hashomer Affiliated to Sackler School of Medicine, Tel-Aviv University, Tel Hashomer, Israel.

United European gastroenterology journal

|March 27, 2024

概括

针对炎症性肠病 (IBD) 的小分子药物可能具有复杂的药物相互作用 (DDI). 医生应该在开处方这些药物之前审查潜在的相互作用,以确保患者的安全.

科学领域:

药理学药理学是指药理学的学科.
胃肠病学胃肠病学

背景情况:

小分子药物越来越多地用于炎症性肠道疾病 (IBD).
与单克隆抗体不同,小分子具有复杂的药理动力学,受到药物相互作用 (DDI),患者因素和食物的影响.
了解这些相互作用对于安全有效的IBD治疗至关重要.

研究的目的:

为IBD医生提供关于小分子药物相互作用的实用指南.
审查IBD中使用的五种新型小分子的药理动力学和已知的相互作用.
突出评估DDI对小分子IBD疗法的临床相关性的挑战.

主要方法:

在DDI中涉及的关键药物代谢酶和载体的概述.
解释FDA对药物相互作用危险值的方法.
托法西提尼布,乌帕达西提尼布,菲尔戈提尼布,奥扎尼莫德和埃特拉西莫德的药理动力学和DDI的详细综述.

主要成果:

治疗IBD的小分子药物,如托法西替尼和奥扎尼莫德,具有复杂的药理动力学特征.
存在许多潜在的DDI,受代谢酶,转运体和患者特定因素的影响.
在准确确定这些相互作用的规模和临床意义方面仍然存在挑战.

结论:

在处方小分子IBD药物之前,医生必须仔细评估潜在的DDI.
医疗保健专业人员和患者的提高意识可以减轻与小分子DDI相关的风险.
积极管理DDI对于优化小分子治疗IBD患者的治疗结果至关重要.

关键词:

IBD IBD IBD IBD IBD IBD IBD IBD IBD IBD IBD IBD IBD IBD IBD 埃特拉西莫德的使用方法菲尔戈提尼布 (filgotinib) 是一种药物.臭氧化的使用方法小分子药物小分子药物托法西提尼布 (tofacitinib) 是一种在此之前,upadacitinib 已经在使用中.

更多相关视频

Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease

Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease

Published on: September 20, 2018

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

相关概念视频

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...

Drugs for Treatment of Ulcerative Colitis in IBD

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...